Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825107 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL29986711 | 0.85 | MAPT (0.68) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL365353 | 0.85 | MAPT (0.68) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL29664708 | 0.82 | CES2 (0.59) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL5393044 | 0.82 | ALDH1A1 (0.64) | ALDH1A1MAPTMEN1KMT2ACA12 | |
| SCHEMBL29822834 | 0.82 | ALDH1A1 (0.64) | ALDH1A1MAPTMEN1KMT2ACA12 | |
| SCHEMBL383936 | 0.82 | CES2 (0.59) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL14012582 | 0.82 | CES2 (0.59) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL27692803 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL8122849 | 0.81 | CA1 (0.52) | ALDH1A1MAPTMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20220280495-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220280495-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4039256-A1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND DASATINIB OR NILOTINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA | Amgen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022117882-A2 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2022-06-09 | — | — | WO | disclosed |
| CN-112933236-A | Combination therapy comprising an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer | 美国安进公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10881648-B2 | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10881648-B2 | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2021-01-05 | — | — | US | disclosed |
| WO-2015070224-A2 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070224-A2 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8952036-B2 | Benzoic acid derivative MDM2 inhibitor for the treatment of cancer | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952036-B2 | Benzoic acid derivative MDM2 inhibitor for the treatment of cancer | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952036-B2 | Benzoic acid derivative MDM2 inhibitor for the treatment of cancer | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2014134201-A1 | A BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134201-A1 | A BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140243372-A1 | BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243372-A1 | BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243372-A1 | BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243372-A1 | BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | MDM2, TP53, BCCIP | ALDH1A1 495/4885MAPT 1498/4885MEN1 1662/4885 |
| US-10881648-B2 | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | MDM2, TP53, CDKN1A | ALDH1A1 875/4885MAPT 1221/4885MEN1 512/4885 |
| US-20220280495-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | MDM2, TP53, CDKN1A | ALDH1A1 875/4885MAPT 1221/4885MEN1 512/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | ALDH1A1 1523/4885MAPT 3395/4885MEN1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.